Cancer cells divide and multiply rapidly within the brain metastases in the brain. These cancer cells carry special types of electrically charged elements that play a role during the cell division process. Other healthy cells in the brain multiply at a much slower rate, if at all, and thus rarely include the same electric properties as the dividing cancer cells.
TTFields Mechanism of Action
The NovoTTF-100M device used in this trial delivers very low intensity, alternating electric fields to the tumor site through the scalp. These fields are known as Tumor Treating Fields or TTFields. Due to the unique shape of cancer cells when they are multiplying, TTFields have been shown to cause the building blocks of these cells to pile up in such a way that the cells physically break apart. In addition, cancer cells also contain miniature building blocks that move essential parts of the cells from place to place during division. TTFields have been shown to cause these building blocks to fall apart since they have a special type of electric charge. As a result of these two effects, preliminary study data indicate that cancer tumor growth is inhibited after continuous exposure to TTFields. Preliminary data also indicate that the TTFields affect the healthy brain cells much less than cancer cells since healthy brain cells multiply at a much slower rate, if at all.
A summary of TTFields’ mechanism of action is illustrated in the following animation:
TTFIELDS ARE NOT APPROVED FOR THE TREATEMENT OF BRAIN METASTASIS. THE SAFETY AND EFFICACY OF TTFIELDS FOR BRAIN METASTASIS HAS NOT BEEN ESTABLISHED.
Past clinical experience
A number of systems developed to deliver TTFields to different tumors have been tested to date. The main difference between the previously tested systems and the NovoTTF-100M is the frequency of TTFields provided by each system. The frequency is adjusted by the manufacturer of the systems in order to optimize the treatment for each treated cancer, based on data from laboratory experiments.
The NovoTTF-100A System is approved by the FDA for the treatment of newly diagnosed and recurrent GBM. The same system has a CE Mark in Europe for the treatment of GBM (for more information about the approved indications for use, please consult with your doctor or refer to the product information sheet).
Based on the science behind TTFields and the clinical results to date, the NovoTTF-100M System is not expected to have systemic side effects in patients suffering from brain metastasis from non-small cell lung cancer. In previous studies performed with the NovoTTF-100A System, many patients have experienced local skin irritation beneath the transducer arrays.
In a previous clinical trial for recurrent GBM, the following device related adverse events were reported:
In the aforementioned study for non-small cell lung cancer, there were no serious side effects related by the study doctors to TTFields. The only side effect which was related to the NovoTTF-100L System was mild to moderate skin irritation under the transducer arrays placed on the skin.
The information provided in this website is partial, and you should consult with your treating physician concerning the complete safety profile of TTFields.
Please note that while the adverse event information from the recurrent GBM and the lung cancer trials may be relevant to use of the device for brain metastasis from non-small cell lung cancer, it is not specific to this condition. The safety profile of the device for brain metastasis from non-small cell lung cancer may be different.